![]() |
|
|
Vol. 281, Issue 1, 173-179, 1997
Department of Toxicology and Pharmacology, Faculty of
Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
A novel derivative of diltiazem (1,5-benzothiazepine
Ca++ antagonist), DTZ323,
3-(acetyloxy)-5-[2-[[2-(3,4-dimethoxyphenyl)ethyl]-methylamino]ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5H)-one, was characterized by radioligand binding experiments with rabbit skeletal T-tubule membranes in terms of the affinity and the
selectivity to the binding sites for the three classical calcium
antagonists, such as dihydropyridines, phenylalkylamines and
benzothiazepines. DTZ323, like diltiazem and clentiazem, exhibited
complete and concentration-dependent inhibition of
d-cis-[3H]diltiazem binding to the
membrane with a slope factor close to unity.
Ki values indicated that DTZ323
(Ki = 6.6 ± 0.6 nM, mean ± S.E.,
n = 4) was 48 times and 9 times more potent than diltiazem and clentiazem, respectively. DTZ323 partially inhibited the
specific binding of a dihydropyridine ligand,
(+)-[3H]PN200-110, at 37°C. The equilibrium saturation
study showed that DTZ323 reduces the affinity for the
(+)-[3H]PN200-110 binding in a concentration-dependent
manner with a slight decrease in the density of the binding sites.
DTZ323 also inhibited the specific binding of a phenylalkylamine
ligand, (
)-[3H]D888, completely as did diltiazem.
DTZ323 (1 µM) had no effect on the dissociation rate of
d-cis-[3H]diltiazem at 2°C, whereas 30 µM verapamil increased the dissociation rate, which suggested that
DTZ323 inhibits the specific binding of
d-cis-[3H]diltiazem in a manner similar to
other competitive ligands for the benzothiazepine binding site. These
results indicate that DTZ323 is a selective ligand for the
1,5-benzothiazepine binding site with the highest affinity among the
diltiazem derivatives.